

Special Issue

Fascin in Cancer, from Prognostic Marker to Molecular Target

Message from the Guest Editor

Metastasis is the cause of over 90% of deaths due to cancer. In order for the tumor cell to acquire an invasive and metastatic phenotype, specific cytoskeleton rearrangements are needed which mainly involve actin. Fascin is the key protein in actin bundling, which a crucial process for generation of invasive structures such as lamellipodia and invadopodia. Moreover, fascin contributes to metastasis by altering mitochondrial function and metabolic stress resistance. Not surprisingly, fascin overexpression is associated with tumors with aggressive behavior, high metastatic potential, and resistance to chemotherapy, and in most cases, available targeted therapies are lacking. Recent X-ray crystal structures of fascin bound to chemical compounds have opened the possibility for specific drugs designed to target this protein which plays a causative role in tumor progression. This Special Issue will cover the different functions of fascin in tumor development and promotion, its value as prognostic marker in cancer, and promising advances in the design of chemical compounds targeting this actin-bundling protein.

Guest Editor

Prof. Dr. Pablo Conesa-Zamora

Molecular Pathology and Pharmacogenetic Group (Institute for Biomedicine Research from Murcia (IMIB)), Spain

Deadline for manuscript submissions

closed (15 September 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/43560

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)